DOCSLIB.ORG

Appendix One the CELLTECH CASE STUDY

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Appendix One the CELLTECH CASE STUDY City Research Online City, University of London Institutional Repository Citation: Mc Namara, P. (2000). Managing the tension between knowledge exploration and exploitation: the case of UK biotechnology. (Unpublished Doctoral thesis, City University London) This is the accepted version of the paper. This version of the publication may differ from the final published version. Permanent repository link: https://openaccess.city.ac.uk/id/eprint/7870/ Link to published version: Copyright: City Research Online aims to make research outputs of City, University of London available to a wider audience. Copyright and Moral Rights remain with the author(s) and/or copyright holders. URLs from City Research Online may be freely distributed and linked to. Reuse: Copies of full items can be used for personal research or study, educational, or not-for-profit purposes without prior permission or charge. Provided that the authors, title and full bibliographic details are credited, a hyperlink and/or URL is given for the original metadata page and the content is not changed in any way. City Research Online: http://openaccess.city.ac.uk/ [email protected] Managing the Tension Between Knowledge Exploration and Exploitation: The Case of UK Biotechnology By Peter Mc Namara Presented in fulfilment of the requirements of the: Degree of Doctor of Philosophy Strategy and International Business City University Business School Department of Strategy and Marketing March 2000 TABLE OF CONTENTS ACKNOWLEDGEMENTS ........................................................................................................................... 14 DEDICATION .......................................................................................................................... 16 ABSTRACT .......................................................................................................................... 17 CHAPTER ONE INTRODUCTION RESEARCHQUESTIONS ................................................................................................................. 20 1. FROM A TI IEORFTICAL PERSPECTIVE. WHAT IS THE KNOWLEDGE EXPLORATION/EXPLOITATION DII.EMMA?......................................................................................................................................20 2. Is THERE EVIDENCE WITHIN A REAL ORGANISATIONAL CONTEXT THAT A FIRM'S ACTIVITIES CAN BE EXPLAINED THROUGH TUE CONCEPTUAL LENS OF BALANCING A TENSION BETWEEN KNOWLEDGE EXPLORATIONAND EXPLOITATION9..............................................................................................21 3. Do THE FINANCIAL MARKETS REWARD ANNOUNCEMENTS OF EXPLOITATION ACTIVITIES WITH HIGHER RETURNS THAN EXPLOR.\TION ACTIVITIES, AS PREDICTED BY THEORY9...........................22 INDUSTRIALCONTEXT ................................................................................................................. 23 BIOTECHNOLOGYDEFINED ............................................................................................................23 APPLICATIONSOF BIOTECHNOLOGY AND REGULATION..................................................................24 PATENTS: THE REWARD FOR HIGH JUSKS AND COSTS OF REGULATORY APPROVAL.........................25 BIOTECHNOLOGYAND THE PHARMACEUTICAL SECTOR.................................................................28 SA1IPLE SELECTION .32 UK BIOTECHNOLOGY AND THE TENSION BETWEEN EXPLORATION ANEXPLOITATION ACTIVITIES ........................................................32 SELECTIONOF SAMPLE COMPANIES ...............................................................................................33 STRUCTUREOF THESIS ................................................................................................................. 36 CHAPTER TWO THE ANTAGONISTIC NATURE OF KNOWLEDGE MANAGEMENT: THE BALANCE BETWEEN KNOWLEDGE EXPLORATION AND EXPLOITATION INTRODUCTION .............................................................................................................................. 45 CONTRIBUTIONOF THIS CHAPTER..................................................................................................48 STRUCTUREOF THIS CHAPTER ....................................................................................................... 49 EXPLORATION/EXPLOITATION AS A TRIAD: EXPLORATION, DEVELOPMENT AND USEFOR APPROPRIATION ........................................................................................................... 51 EXPLOR:\TION................................................................................................................................51 DFVEIOPMENT ..............................................................................................................................53 The11,1k heg tee,z Exploration azd Dei'elopnent.....................................................................54 DistziiguLslung Developuienifroin Use for Appropriation ......................................................58 Usi: FOR APPROI'RIM IO\ .............................................................................................................. 59 PROI'osmoNs: VAI.IE AI)DEI) AND KNOWLEDGE EXPLORATION EXPLOITATION..........................61 NOXAKA'S KNOWLEDGE SPIRAL AND EXPLORATION/EXPLOITATION ...................... 64 ANTAGONISTIC PROCESSES ........................................................................................................ 67 CURl: RIGIDITIES ...........................................................................................................................67 SIOW RA Fl: OF Ll:RNING.............................................................................................................68 IMITATION.....................................................................................................................................70 COMPLEMENTARITYOF ANTAGONISTS.......................................................................................... 71 SOME PI\OTAL CHARACTERISTICS IN THE ANTAGONISTIC NATURE OF KNOWLEDGEMANAGEMENT ..................................................................................................... 72 MOVEMENTS BETWEEN THE PROCESSES OF EXPLORATION AND CORE RIGIDITY (FIGURE Two).. 72 Mavericks................................................................................................................................74 PersonnelTurnove...................................................................................................................75 Unlearning..............................................................................................................................76 MOVEMENTS BETWEEN THE PROCESSES OF DEVELOPMENT AND SLOW RATE OF LEARNING (FIGURE THREE) .......................................................................................................................................... 77 Slack ........................................................................................................................................ 79 CommonCodes and Shared Language ................................................................................... 81 Experimentation ...................................................................................................................... 82 MOVEMENTS BETWEEN THE PROCESSES OF USE FOR APPROPRIATION AND IMITATION (FIGURE FouR) ............................................................................................................................................ 83 COMPLEM ENTA RITY AND ANTAGONISM BETWEEN CHARACTERISTICS..........................................87 CONCLUSION .................................................................................................................................... 88 CHAPTER THREE BALANCING KNOWLEDGE EXPLORATION AND EXPLOITATION IN A REAL ORGANISATION OVER TIME: LESSONS FROM THE CELLTECH CASE INTRODUCTION ................................................................................................ 97 THEORV.............................................................................................................................................. 98 METHODS AND DATA COLLECTION ..................................................................................... 101 Sot R( I S OF D.i .. VALII)ITV .\D RLLIAI3II ITY ........................................................................ 101 Till I\1 I R\ IFW I'ROCI SS ............................................................................................................. 102 CI .ssII IC 1 I0\ UI ACTI\'ITIFs As EXPlORATION AND EXPLOITATION ....................................... 104 AN OVERVIEW OF CELLTECH .................................................................................................. 107 EXPLORATION/EXPLOITATION AS A LENS IN UNDERSTANDING CELLTECH'S RENEWAL ....................................................................................................................................... 110 EXPLORATIONEXPLOITATIoN INSIDF THERAPEUTICS ................................................................. 112 FROM CORE RIGIDITIES TO EXPLORATION FOR NEW CORE CAPABILITIES: ACTIONS TAKEN TO PROMOTE EXPLORATION AND EXPLOITATION INSIDE CELLTECH ....................................................................................................................................... T16 CRLATINGA CRISIS ...................................................................................................................... 117 UNLEARNING, REORGANISING AND NEW RECRUITS......................................................................119
Load more

Recommended publications
  • Biotechnology and the Economics of Discovery in the Pharmaceutical Industry
    BIOTECHNOLOGY AND THE ECONOMICS OF DISCOVERY IN THE PHARMACEUTICAL INDUSTRY HELEN SIMPSON Office of Health Economics 12 Whitehall London SWlA 2DY ©October 1998. Office of Health Economics. Price £7.50 ISBN 1 899040 60 9 Printed by BSC Print Ltd, London. About the Author Helen Simpson is currently a researc~ economist at the Institute for Fiscal Studies and was formerly an economist at the Department of Trade and Industry. However, the opinions expressed here are her own and do not necessarily reflect the views of the IFS or of DTI officials or ministers. Acknowledgements This paper has been developed from my MPhil Economics thesis Scientist Entrepreneurs and the Finance of Biotech Companies. I would like to thank Margaret Meyer, Paul David and Gervas Huxley for their valuable suggestions. I am particularly grateful to Hannah Kettler and Jon Sussex for their advice and editorial inputs to the paper. My thanks also go to Adrian Towse and members of the OHE Editorial Board for their comments, and to the following individuals who gave me their insights into the pharmaceutical industry: Dr Trevor Jones, Director General, ABPI; Dr Janet Dewdney, Chairman, Adprotech; Dr Clive Halliday, Head of Global External Scientific Affairs, Glaxo Wellcome; Mr Alan Galloway, Head of Research Administration, Dr Nick Scott-Ram, Director of Corporate Affairs, and Dr Philip Huxley, all of British Biotech; Christine Soden, Finance Director, Chiroscience; Ian Smith, Lehman Brothers Pharmaceutical Research; and Paul Murray, 31. The Office of Health Economics Terms of Reference The Office of Health Economics (OHE) was founded in 1962. Its terms of reference are to: • commission and undertake research on the economics of health and health care; • collect and analyse health and health care data from the UK and other countries; • disseminate the results of this work and stimulate discussion of them and their policy implications.
    [Show full text]
  • Chrysler Affiliate Rewards Program
    Chrysler Affiliate Rewards Program If you or your spouse work, or have retired from, one of the companies listed below, you may qualify for pricing as low as 1% Below Factory Invoice on a New FIAT! Check the list of companies below to see if your company qualifies.* A F O AAA-- State of Ohio Members Freightliner Of Tampa, Llc Ocala Freightliner ABB, Inc. Freightliner Of Toledo OCE'- North America Abbott Labs Freightliner Of Utah, Llc Ocean Freightliner, Ltd. Abbott, Nicholson, Quilter, Freightliner Trucks So. Florida Inc. O'connor Gmc, Inc. Esshaki & Youngblood PC Freightliner Twin Ports O'connor Truck Sales, Inc. Abercrombie & Fitch Freightmasters Ohio Machinery Company AboveNet Fresenius Medical dba Ohio CAT Abraxis Bioscience Inc. Fresno Truck Center Oklahoma City Freightliner Accor North America FRIENDLY MOTORCARS Oklahoma Farm Bureau Ace Hardware Corporation Fru-Con Construction Corporation Oklahoma Publishing Company, Action Western Star Fujisawa Healthcare Inc. The (OPUBCO) Actelion Pharmaceuticals US, Inc. Ftl And Ws Of Maine Old Dominion Freight Lines Action Couriers Ftl And Wst Of Tifton Oldcastle Inc. ADVANTAGE Health Solutions, Inc. Ftl Stl Wst Of Odessa Omaha Truck Center Inc Advance Publications Ftl Trucks Of South Florida Omni Care Health Plan Aearo Company Ftl, Stl And Wst Of Montgomery One Call Locators Aetna Ftl,Stl, and Western Star Of Dothan One Source Management Inc Affinia Group Fyda Freightliner Cincinnati Oracle Corporation Agar Truck Sales, Inc. Fyda Freightliner Columbus,Inc Organon Pharmaceuticals USA, Inc. AGCO Corporation Fyda Freightliner Pittsburgh Orlando Freightliner AGFA Corporation Fyda Freightliner Youngstown Orlando Freightliner South Aggreko, LLC ORRIN B HAYES, INC. Agricredit Acceptance LLC G Oscient Pharmaceuticals Agrilink Foods OSI Pharmaceuticals Gabrielli Ford Truck Sales AGSTAR Financial Services Otjen, Van Ert, Stangle, Lieb & Weir, S.C.
    [Show full text]
  • Programme 10.00 Registration 10.20 Welcome from the Host
    Leadership Seminar: Respiratory and Inflammatory Diseases 22 September 2016 Penningtons Manches, 125 Wood Street, London EC2V 7AW Sponsored by Hosted by Programme 10.00 Registration 10.20 Welcome from the Host 10.30 Introduction Adrian Dawkes, PharmaVentures 10.45 Keynote presentations and discussion on unmet clinical needs including: 10.45 Symptoms vs Disease Modification Approach Lars Larson, TranScrip 11.05 Prospects for the prevention and treatment of respiratory virus-induced exacerbations in asthma and COPD Garth Rapeport, Pulmocide 11.25 Eosinophil depletion with benralizumab (anti-IL-5R) for the management of Severe Asthma and Chronic Obstructive Pulmonary Disease (COPD) Suzanne Cohen, MedImmune 11.45 Breath Biopsy - Breath Volatile Organic Compounds (VOCs) as Markers for Respiratory Disease Billy Boyle, Owlstone Medical 12.05 Panel discussion and Q&A 12.30 Lunch and networking 14.00 Data Protection and Liability in Respiratory Connected Devices Oliver Bett, Penningtons Manches 14.20 Adaptive Design in Respiratory Clinical Trials – A Sponsor’s Business Case Alethea Wieland, Scope International 14.40 Development of Immunoassays and Point-of-Care Tests for the Measurement of Active Protease Biomarkers of Chronic Respiratory Disease David Ribeiro, ProAxsis 15.00 Aiming for the Lungs - Formulation Strategies for Delivery of Inhaled Biologics Charlotte Yates, Vectura 15.30 Tea, coffee and networking 16.00 Innovative therapeutic options 16.00 The Development of an IL-17BR therapeutic antibody for the treatment of Asthma and IPF David Matthews, MRC Technology 16.20 Mycobacterium Tuberculosis Derived Peptide as a Disease Modifying Therapy for Asthma Nicky Cooper, Peptinnovate 16.40 Closing Remarks and Drinks Reception 18.00 Event closes Speaker Profiles Oliver Bett Associate, Penningtons Manches Oliver is an associate in our IP, IT and commercial team of Penningtons Manches, based in the London office.
    [Show full text]
  • United States Securities and Exchange Commission Form 10-K Shire Pharmaceuticals Group
    UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K (Mark One) ፤ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 1999 អ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission file number 0-29630 SHIRE PHARMACEUTICALS GROUP PLC (Exact name of registrant as specified in its charter) England and Wales (State or other jurisdiction (I.R.S. Employer of incorporation or organization) Identification No.) N.A. East Anton, Andover, Hampshire SP10 5RG England (Address of principal executive offices) (Zip Code) 44 1264 333455 (Registrant's telephone number, including area code) Securities registered pursuant to Section 12(b) of the Act: Title of each class Name of exchange on which registered American Depository Shares, each representing Nasdaq National Market 3 Ordinary Shares, 5 pence nominal value per share Securities registered pursuant to Section 12(g) of the Act: None (Title of class) Indicate by check mark whether the Registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the Registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ፤ No អ Indicate by check mark if disclosure of delinquent filers pursuant to Item 405 of Regulation S-K is not contained herein, and will not be contained, to the best of the Registrant's knowledge, in definitive proxy or information statements incorporated by reference to Part III of this Form 10-K or any amendment to this Form 10-K.
    [Show full text]
  • SHIRE PLC (Exact Name of Registrant As Specified in Its Charter)
    UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K [X] ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2009 [ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission file number 0-29630 SHIRE PLC (Exact name of registrant as specified in its charter) Jersey (Channel Islands) 98-0601486 (State or other jurisdiction of incorporation or (I.R.S. Employer Identification No.) organization) 5 Riverwalk, Citywest Business Campus, Dublin +353 1 429 7700 24, Republic of Ireland (Address of principal executive offices and zip code) (Registrant’s telephone number, including area code) Securities registered pursuant to Section 12(b) of the Act: Title of each class Name of exchange on which registered American Depositary Shares, each representing three NASDAQ Global Select Market Ordinary Shares 5 pence par value per share Securities registered pursuant to Section 12(g) of the Act: None (Title of class) 1 Indicate by check mark whether the Registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act Yes [X] No [ ] Indicate by check mark if the Registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act Yes [ ] No [X] Indicate by check mark whether the Registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the Registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.
    [Show full text]
  • Annual Report 2008 Find out More About GSK Online…
    Do more, feel better, live longer Grow Deliver Simplify Annual Report 2008 Find out more about GSK online… www.gsk.com Website GlaxoSmithKline’s website www.gsk.com gives additional information on the Group. Information made available on the website does not constitute part of this Annual Report. Notice regarding limitations on Director liability under English Law Under the UK Companies Act 2006, a safe harbour limits the liability of Directors in respect of statements in and omissions from the Report of the Directors contained on pages 12 to 98. Under English law the Directors would be liable to the company (but not to any third party) if the Report of the Directors contains errors as a result of recklessness or knowing misstatement or dishonest concealment of a material fact, but would not otherwise be liable. Report of the Directors Pages 12 to 98 inclusive consist of a Report of the Directors that has been drawn up and presented in accordance with and in reliance upon English company law and the liabilities of the Directors in connection with that report shall be subject to the limitations and restrictions provided by such law. Cautionary statement regarding forward-looking statements The Group’s reports filed with or furnished to the US Securities and Exchange Commission (SEC), including this document and written information released, or oral statements made, to the public in the future by or on behalf of the Group, may contain forward-looking statements. Forward-looking statements give the Group’s current expectations or forecasts of future events. A shareholder can identify these statements by the fact that they do not relate strictly to historical or current facts.
    [Show full text]
  • FY06 Pharmaceutical Marketing Disclosures Report
    Pharmaceutical Marketing Disclosures For the period July 1, 2005 to June 30, 2006 Report of Vermont Attorney General William H. Sorrell June 26, 2007 Contact: Julie Brill Assistant Attorney General (802) 828-5479 Pharmaceutical Marketing Disclosures: Report of Vermont Attorney General William H. Sorrell on Payments to Physicians June 26, 2007 Index Page: I. Executive Summary 3 II. Description of Vermont’s Payment Disclosure Law 4 III. Amendments to Prior Pharmaceutical Marketing Disclosure Reports filed by the Vermont Attorney General's Office 5 IV. Summary of Pharmaceutical Marketing Expenditures 6 1. Total Payments of Each Pharmaceutical Manufacturer 6 2. Payments of all Manufacturers Organized by Recipient Type 7 3. Payments by Nature of Expenditure 10 4. Payments by Purpose of Expenditure 10 5. Trade Secret Declarations 11 V. Enforcement Actions 12 Appendix: Tab 1: 33 V.S.A. §2005 13 Tab 2: FY 06 Tables 17 Tab 3: FY 05 Tables as Revised 25 Tab 4: FY 04 Tables as Revised 34 Tab 5: FY 03 Tables as Revised 43 2 Pharmaceutical Marketing Disclosures: Report of Vermont Attorney General William H. Sorrell on Payments to Physicians June 26, 2007 I. Executive Summary This is the fourth report of Vermont Attorney General William H. Sorrell on Pharmaceutical Marketing Disclosures. It is based upon disclosures pertaining to payments made during the period July 1, 2005, through June 30, 2006 (FY 06) by pharmaceutical marketers, of the amount of money the companies paid during the past fiscal year on consulting and speaker fees, travel expenses, gifts, and other payments to physicians, hospitals, universities and others authorized to prescribe or dispense pharmaceutical products.
    [Show full text]
  • Consolidation Revisited Is the Founder of Managing Resources, a Date Received *In Revised Form) 8Th October, 2001 Consultancy Focused on the Life Science Industries
    Alan Williams Consolidation revisited is the founder of Managing Resources, a Date received *in revised form) 8th October, 2001 consultancy focused on the life science industries. The Alan Williams company undertakes strategic assignments and also assists public and private sector clients with regulatory affairs, investor Abstract In 1998, the author produced two papers that argued that consolidation was relations and human a necessary activity for biotechnology companies to pay greater attention to. Three resources development. years later a further consideration of the subject seems worthwhile. Examples of Alan has also been an investment manager in successful consolidators are reviewed. a venture capital company, and held Keywords: consolidation, mergers, acquisitions marketing and licensing positions in Fisons. Introduction drink, vaccines and animal health but there is now greater focus on the highest In the early/mid-1970s, the pharmaceutical pro®tability sector, human pharmaceuticals. industry consisted of more than 100 At the time of writing, GSK is rumoured to research-based businesses of some be a possible purchaser of Bayer's signi®cant size, although none of them pharmaceutical business, the future of could convincingly claim a global presence. which has been questioned after the Typically, a leading company had a strong withdrawal of cerivastatin. position in its local market "examples Aventis, the eighth largest pharmaceutical included Merck and P®zer in the USA, company by sales in 2000,1 includes the Bayer in Germany, Beecham in the UK, operations of 1970s companies such as Roussel-Uclaf in France and Fujisawa in Rhone-Poulenc, Rorer, Fisons, Hoechst, Japan) and possibly some other Marion, Richardson Merrell, and some neighbouring countries "US companies in smaller companies.
    [Show full text]
  • Arecor Therapeutics Plc (The “Company”)
    THIS DOCUMENT IS IMPORTANT AND REQUIRES YOUR IMMEDIATE ATTENTION. If you are in any doubt about the contents of this document or the action you should take, you are recommended to seek your own independent financial advice from your stockbroker, bank manager, solicitor, accountant or other independent professional adviser authorised under the Financial Services and Markets Act 2000, as amended, (the “FSMA”) who specialises in advising on the acquisition of shares and other securities if you are resident in the United Kingdom or, if not, from another appropriately authorised independent adviser. This document, which comprises an AIM admission document drawn up in accordance with the AIM Rules for Companies, has been issued in connection with an application for admission to trading on AIM of the entire share capital, issued and to be issued pursuant to the Placing, of Arecor Therapeutics plc (the “Company”). This document does not constitute an offer or any part of any offer of transferable securities to the public in the United Kingdom within the meaning of section 102B of the FSMA or otherwise. Accordingly, this document does not constitute a prospectus for the purposes of section 85 of the FSMA or otherwise and has not been drawn up in accordance with the Prospectus Regulation Rules and has not been nor will it be filed with or approved by the Financial Conduct Authority (“FCA”) or any other competent authority. Application has been made for the Ordinary Shares to be admitted to trading on AIM. It is expected that Admission will become effective and that trading in the Ordinary Shares will commence on AIM at 8.00 a.m.
    [Show full text]
  • Overview of Ftc Actions in Pharmaceutical Products and Distribution*
    OVERVIEW OF FTC ACTIONS IN PHARMACEUTICAL PRODUCTS AND DISTRIBUTION* Health Care Division Bureau of Competition Federal Trade Commission Washington D.C. 20580 Markus H. Meier Assistant Director Bradley S. Albert Deputy Assistant Director Kara Monahan Deputy Assistant Director September 2019 * Actions involving health care services and products are contained in a separate document, Overview of FTC Actions in Health Care Services and Products. Information about advisory opinions in the health care and pharmaceutical sectors is contained in the document Topic and Yearly Indices of Health Care Antitrust Advisory Opinions by Commission and by Staff. TABLE OF CONTENTS I. INTRODUCTION ...............................................................................................................1 II. CONDUCT INVOLVING PHARMACEUTICAL PRODUCTS .......................................3 A. Monopolization ........................................................................................................3 B. Agreements Not to Compete ..................................................................................14 III. CONDUCT INVOLVING PHARMACEUTICAL DISTRIBUTION ..............................20 A. Monopolization ......................................................................................................20 B. Agreements on Price and Price-Related Terms .....................................................20 C. Agreements to Obstruct Innovative Forms of Health Care Delivery or Financing................................................................................................................27
    [Show full text]
  • UNITED STATES SECURITIES and EXCHANGE COMMISSION Washington, D.C
    UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K/A (Amendment No. 1) [ X ] Annual Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 OR Transition Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 for the Transition Period from ________ to ________ For the fiscal year ended Commission File number 0-50626 December 31, 2005 CYCLACEL PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 91-1707622 (State or other jurisdiction (I.R.S. Employer of incorporation or organization) Identification No.) 150 John F. Kennedy Parkway, Suite 100 Short Hills, NJ 07078 (Address of principal executive office) Registrant’s telephone number, including area code (732) 225-8910 Securities registered pursuant to Section 12(b) of the Act: NONE Securities registered pursuant to Section 12(g) of the Act: Common Stock, par value $0.001 per share 6% Convertible Exchangeable Preferred Stock, par value $0.001 per share (Title of class) Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Exchange Act of 1934. Yes No Indicate by check mark if the registrant is not required to file reports required to be filed by Section 13 or Section 15(d) of the Act. Yes No Indicate by check mark whether the Registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the Registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.
    [Show full text]
  • Case No COMP/M.1846 - GLAXO WELLCOME / SMITHKLINE BEECHAM
    EN Case No COMP/M.1846 - GLAXO WELLCOME / SMITHKLINE BEECHAM Only the English text is available and authentic. REGULATION (EEC) No 4064/89 MERGER PROCEDURE Article 6(1)(b) NON-OPPOSITION Date: 08/05/2000 Also available in the CELEX database Document No 300M1846 Office for Official Publications of the European Communities L-2985 Luxembourg COMMISSION OF THE EUROPEAN COMMUNITIES Brussels, 08.05.2000 In the published version of this decision, some PUBLIC VERSION information has been omitted pursuant to Article 17(2) of Council Regulation (EEC) No 4064/89 concerning non-disclosure of business secrets and MERGER PROCEDURE other confidential information. The omissions are ARTICLE 6(2) DECISION shown thus […]. Where possible the information omitted has been replaced by ranges of figures or a general description. To the notifying parties Dear Sirs, Subject: Case No COMP/M.1846-GLAXO WELLCOME/SMITHKLINE BEECHAM Notification of 20.3.2000 pursuant to Article 4 of Council Regulation No 4064/89 1 1. On 20 March 2000, the Commission received a notification of a proposed concentration pursuant to Article 4 of Council Regulation (EEC) No 4064/89 (“the Merger Regulation”) by which the undertaking Glaxo Wellcome plc (“GW”) and SmithKline Beecham plc (“SB”) notified their intention to enter into a full merger within the meaning of Article 3(1)a of the Merger Regulation. The merger was announced on 17 January 2000. 2. In the course of the proceedings, the parties submitted undertakings designed to eliminate competition concerns identified by the Commission, in accordance with Article 6(2) of the Merger Regulation. In the light of these modifications, the Commission has concluded that the notified operation falls within the scope of the Merger Regulation as amended and does not raise serious doubts as to its compatibility with the common market and with the functioning of the EEA Agreement.
    [Show full text]